在持久性低血压的危急病患者中,用于血管压缩器断奶的德罗克西多巴:多中心,回顾性,单臂观察性研究
Andrew J Webb1, Gianna Lh Casal1, Kelly A Newman1
1Department of Pharmacy, Massachusetts General Hospital, Boston, USA.
Journal of intensive care medicine
|August 7, 2024
概括
德罗克西多巴可以帮助关键病患者脱离血管压缩剂,从而可能缩短停止治疗的时间. 它的使用显示了降低了血管压缩剂的需求,并改善了平均动脉压,而不会增加心率.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 长时间使用血管压缩剂是延迟重症监护室 (ICU) 释放的常见原因.
- 探索辅助口服药物,以加快血管压缩剂的停用.
研究的目的:
- 描述droxidopa在患有长期低血压的危急病患者的血管压缩器断奶的使用情况.
- 评估droxidopa在这个患者群体中的疗效和安全性.
主要方法:
- 在两个学术中心进行了回顾性,单臂的观察性研究 (06/2016-07/2023).
- 包括成人ICU患者接受droxidopa为血管压缩剂断奶;不包括那些以前使用或其他迹象的人.
- 主要结局:暂停血管压缩剂的时间 (停用≥24小时).
主要成果:
- 30名患者符合标准;心脏/心脏外科ICU中平均年龄为62,73%.
- 暂停血管压缩剂的中位时间为70小时.
- 开始后,上腺素相当量下降 (0.08至0.02毫克克/公斤/分钟,p<0.001),MAP增加 (p=0.008);心率没有变化 (p=0.37).
- 较低的基线诺亚上腺素使用预测了更快的断奶 (<72小时).
- 输卵管给药没有影响停药的时间 (p=0.93).
结论:
- 德罗克西多巴可以作为一种有效的辅助疗法,用于关键病患者的血管压缩器断奶.
- 服用途径 (口服与输卵管) 并没有显著改变结果.
相关概念视频
Antihypertensive Drugs: Vasodilators
492
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
492
Heart Failure Drugs: Diuretics
353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
Heart Failure Drugs: Inotropic Agents
548
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548


